Which has higher valuation and earnings, BWAY or ATRC?

Brainsway has higher earnings, but lower revenue than AtriCure. Brainsway is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 11.33 $7.57M $0.44 33.50 AtriCure $534.53M 4.66 -$11.45M $0.21 233.24

Is BWAY or ATRC more profitable?

Brainsway has a net margin of 15.65% compared to AtriCure's net margin of 1.85%. Brainsway's return on equity of 12.74% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.65% 12.74% 8.17% AtriCure 1.85% 2.34% 1.77%

Does the media prefer BWAY or ATRC?

In the previous week, AtriCure had 4 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for AtriCure and 2 mentions for Brainsway. AtriCure's average media sentiment score of 1.32 beat Brainsway's score of 0.56 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ESTA or BWAY?

In the previous week, Establishment Labs had 2 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Establishment Labs and 2 mentions for Brainsway. Establishment Labs' average media sentiment score of 1.30 beat Brainsway's score of 0.56 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NVCR or BWAY?

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.04 -$136.23M -$1.30 N/A Brainsway $52.22M 11.33 $7.57M $0.44 33.50

Is NVCR or BWAY more profitable?

Brainsway has a net margin of 15.65% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.74% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Brainsway 15.65% 12.74% 8.17%

Does the media refer more to NVCR or BWAY?

In the previous week, Brainsway had 1 more articles in the media than NovoCure. MarketBeat recorded 2 mentions for Brainsway and 1 mentions for NovoCure. NovoCure's average media sentiment score of 1.08 beat Brainsway's score of 0.56 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, BWAY or LMAT?

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 11.33 $7.57M $0.44 33.50 LeMaitre Vascular $249.60M 7.50 $57.73M $2.85 28.72

Does the media favor BWAY or LMAT?

In the previous week, LeMaitre Vascular had 2 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for LeMaitre Vascular and 2 mentions for Brainsway. LeMaitre Vascular's average media sentiment score of 1.66 beat Brainsway's score of 0.56 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to INSP or BWAY?

In the previous week, Inspire Medical Systems had 2 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Inspire Medical Systems and 2 mentions for Brainsway. Inspire Medical Systems' average media sentiment score of 1.32 beat Brainsway's score of 0.56 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainsway (BWAY) Competitors

$14.74 -0.23 (-1.54%)

As of 08/21/2026 04:00 PM Eastern

Compare

BWAY vs. ATRC, ESTA, NVCR, LMAT, and INSP

Should you buy Brainsway stock or one of its competitors? Brainsway's main competitors and comparable companies include AtriCure (ATRC), Establishment Labs (ESTA), NovoCure (NVCR), LeMaitre Vascular (LMAT), and Inspire Medical Systems (INSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Brainsway compare to AtriCure?

Brainsway (NASDAQ:BWAY) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 19.0% of Brainsway shares are owned by insiders. Comparatively, 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, AtriCure had 4 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for AtriCure and 2 mentions for Brainsway. AtriCure's average media sentiment score of 1.32 beat Brainsway's score of 0.56 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Brainsway currently has a consensus price target of $16.95, indicating a potential upside of 14.99%. AtriCure has a consensus price target of $48.50, indicating a potential downside of 0.98%. Given Brainsway's higher probable upside, research analysts plainly believe Brainsway is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

Brainsway has a net margin of 15.65% compared to AtriCure's net margin of 1.85%. Brainsway's return on equity of 12.74% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
AtriCure	1.85%	2.34%	1.77%

Brainsway has higher earnings, but lower revenue than AtriCure. Brainsway is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.33	$7.57M	$0.44	33.50
AtriCure	$534.53M	4.66	-$11.45M	$0.21	233.24

Summary

Brainsway beats AtriCure on 9 of the 17 factors compared between the two stocks.

How does Brainsway compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Brainsway (NASDAQ:BWAY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Brainsway has a net margin of 15.65% compared to Establishment Labs' net margin of -15.82%. Brainsway's return on equity of 12.74% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Brainsway	15.65%	12.74%	8.17%

Establishment Labs has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Brainsway has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	10.26	-$51.06M	-$1.31	N/A
Brainsway	$52.22M	11.33	$7.57M	$0.44	33.50

Establishment Labs presently has a consensus price target of $100.25, indicating a potential upside of 37.95%. Brainsway has a consensus price target of $16.95, indicating a potential upside of 14.99%. Given Establishment Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Establishment Labs is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Establishment Labs had 2 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Establishment Labs and 2 mentions for Brainsway. Establishment Labs' average media sentiment score of 1.30 beat Brainsway's score of 0.56 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Brainsway has a net margin of 15.65% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.74% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Brainsway	15.65%	12.74%	8.17%

NovoCure has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

NovoCure currently has a consensus target price of $21.20, indicating a potential upside of 23.98%. Brainsway has a consensus target price of $16.95, indicating a potential upside of 14.99%. Given NovoCure's higher probable upside, equities research analysts clearly believe NovoCure is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

84.6% of NovoCure shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.04	-$136.23M	-$1.30	N/A
Brainsway	$52.22M	11.33	$7.57M	$0.44	33.50

In the previous week, Brainsway had 1 more articles in the media than NovoCure. MarketBeat recorded 2 mentions for Brainsway and 1 mentions for NovoCure. NovoCure's average media sentiment score of 1.08 beat Brainsway's score of 0.56 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats NovoCure on 12 of the 16 factors compared between the two stocks.

How does Brainsway compare to LeMaitre Vascular?

Brainsway (NASDAQ:BWAY) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Brainsway has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.33	$7.57M	$0.44	33.50
LeMaitre Vascular	$249.60M	7.50	$57.73M	$2.85	28.72

LeMaitre Vascular has a net margin of 25.02% compared to Brainsway's net margin of 15.65%. LeMaitre Vascular's return on equity of 15.63% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
LeMaitre Vascular	25.02%	15.63%	10.06%

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Brainsway currently has a consensus price target of $16.95, indicating a potential upside of 14.99%. LeMaitre Vascular has a consensus price target of $110.60, indicating a potential upside of 35.11%. Given LeMaitre Vascular's higher probable upside, analysts plainly believe LeMaitre Vascular is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, LeMaitre Vascular had 2 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for LeMaitre Vascular and 2 mentions for Brainsway. LeMaitre Vascular's average media sentiment score of 1.66 beat Brainsway's score of 0.56 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

LeMaitre Vascular beats Brainsway on 10 of the 16 factors compared between the two stocks.

How does Brainsway compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Brainsway has a net margin of 15.65% compared to Inspire Medical Systems' net margin of 15.03%. Brainsway's return on equity of 12.74% beat Inspire Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
Brainsway	15.65%	12.74%	8.17%

Inspire Medical Systems has higher revenue and earnings than Brainsway. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	1.98	$145.42M	$4.62	13.52
Brainsway	$52.22M	11.33	$7.57M	$0.44	33.50

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Inspire Medical Systems currently has a consensus target price of $66.19, indicating a potential upside of 5.98%. Brainsway has a consensus target price of $16.95, indicating a potential upside of 14.99%. Given Brainsway's stronger consensus rating and higher possible upside, analysts plainly believe Brainsway is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Inspire Medical Systems has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

In the previous week, Inspire Medical Systems had 2 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Inspire Medical Systems and 2 mentions for Brainsway. Inspire Medical Systems' average media sentiment score of 1.32 beat Brainsway's score of 0.56 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats Inspire Medical Systems on 10 of the 17 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$591.53M	$6.02B	$7.37B	$12.85B
Dividend Yield	N/A	1.75%	2.53%	11.08%
P/E Ratio	33.50	26.67	272.88	24.24
Price / Sales	11.33	45.38	618.96	99.81
Price / Cash	62.96	33.24	78.62	53.99
Price / Book	7.48	6.23	13.05	6.20
Net Income	$7.57M	$150.07M	$3.47B	$348.59M
7 Day Performance	-9.68%	0.69%	2.09%	0.08%
1 Month Performance	-10.72%	8.91%	6.64%	3.88%
1 Year Performance	93.95%	8.07%	25.02%	16.98%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	4.3825 of 5 stars	$14.74 -1.5%	$16.95 +15.0%	+93.9%	$591.53M	$52.22M	33.50	120	Analyst Downgrade
ATRC AtriCure	3.7138 of 5 stars	$45.72 +2.1%	$48.50 +6.1%	+30.1%	$2.33B	$534.53M	217.65	1,300	Positive News Analyst Upgrade
ESTA Establishment Labs	3.5898 of 5 stars	$75.44 -1.5%	$100.25 +32.9%	+66.6%	$2.25B	$245.82M	N/A	1,004
NVCR NovoCure	3.3202 of 5 stars	$17.14 -2.3%	$21.20 +23.7%	+37.6%	$1.99B	$699.19M	N/A	1,605	Positive News
LMAT LeMaitre Vascular	4.8751 of 5 stars	$83.87 +1.6%	$110.60 +31.9%	-18.4%	$1.92B	$249.60M	29.43	490	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. ATRC, ESTA, NVCR, LMAT, and INSP

How does Brainsway compare to AtriCure?

Summary

How does Brainsway compare to Establishment Labs?

Summary

How does Brainsway compare to NovoCure?

Summary

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. ATRC, ESTA, NVCR, LMAT, and INSP

How does Brainsway compare to AtriCure?

Do institutionals & insiders believe in BWAY or ATRC?

Does the media prefer BWAY or ATRC?

Which has more volatility & risk, BWAY or ATRC?

Do analysts prefer BWAY or ATRC?

Is BWAY or ATRC more profitable?

Which has higher valuation and earnings, BWAY or ATRC?

Summary

How does Brainsway compare to Establishment Labs?

Is ESTA or BWAY more profitable?

Which has more volatility & risk, ESTA or BWAY?

Which has better earnings & valuation, ESTA or BWAY?

Do analysts recommend ESTA or BWAY?

Do institutionals and insiders believe in ESTA or BWAY?

Does the media refer more to ESTA or BWAY?

Summary

How does Brainsway compare to NovoCure?

Is NVCR or BWAY more profitable?

Which has more volatility and risk, NVCR or BWAY?

Do analysts recommend NVCR or BWAY?

Do institutionals & insiders believe in NVCR or BWAY?

Which has higher valuation & earnings, NVCR or BWAY?

Does the media refer more to NVCR or BWAY?

Summary

How does Brainsway compare to LeMaitre Vascular?

Which has more risk & volatility, BWAY or LMAT?

Which has higher valuation & earnings, BWAY or LMAT?

Is BWAY or LMAT more profitable?

Do institutionals and insiders hold more shares of BWAY or LMAT?

Do analysts recommend BWAY or LMAT?

Does the media favor BWAY or LMAT?

Summary

How does Brainsway compare to Inspire Medical Systems?

Is INSP or BWAY more profitable?

Which has stronger valuation and earnings, INSP or BWAY?

Do insiders and institutionals believe in INSP or BWAY?

Do analysts recommend INSP or BWAY?

Which has more volatility & risk, INSP or BWAY?

Does the media refer more to INSP or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools